The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

(HealthDay News) — Chronic kidney disease (CKD) reduces quality of life (QoL) for patients and their caregivers globally, according to a study published online Dec. 24 in Advances in Therapy.

When cancer subtypes were examined, the analysis revealed that phototherapy was linked to a 40% increased odds of blood cancers. More modest associations were observed for solid organ cancers and ...

Researchers reported on patient acceptance of an e-consent tool for asynchronous delivery of study information and for receiving consent from patients.

In 2025, the number of all students enrolled in medical school reached 100,723 — a significant milestone for the future of ...

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, ...

Beyond broad recommendations for recurrent kidney stone prevention, clinicians and renal dietitians can create personalized plans.

After controlling for known CV risk factors, all FFR-CT subgroups remained significantly associated with MI, ...

44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

Score had temporal stability for patients with stable kidney function, but was responsive for only some with worsening disease.